The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Glioblastoma multiforme: a review of where we have been and where we are going
Abstract
Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest challenges in the management of cancer patients worldwide, despite notable recent achievements in oncology. Even with aggressive surgical resections using state-of-the-art preoperative and intraoperative neuroimaging, along with recent advances in radiotherapy and chemotherapy, the prognosis for GBM patients remains dismal: median survival after diagnosis is about 14 months. Established good prognostic factors are limited, but include young age, high Karnofsky Performance Status (KPS), high mini-mental status examination score, O6-methylguanine methyltransferase promoter methylation, and resection of > 98% of the tumor. Standard treatment includes resection, followed by concurrent chemotherapy and radiotherapy. GBM research is being conducted worldwide at a remarkable pace, with some of the more recent promising studies focused on identification of aberrant genetic events and signaling pathways, tumor stem cell identification and characterization, modulation of tumor immunological responses, combination therapies, and understanding of the rare long-term survivors. Past treatment strategies have failed for various reasons; however, newer strategies in trials today and on the horizon encourage optimism. To help illustrate 'where we have been' with this fatal disease and 'where we are going' with contemporary studies, we include in this review a detailed history of Phase III clinical trials for GBM, with a final emphasis on exciting new treatment strategies that offer hope for future GBM therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“Recent comprehensive genetic screens of GBM have confirmed that genetic alterations are scattered across the entire genome, affecting numerous chromosomes [3,34].”
BackgroundSelf-citationIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Self-citationLi, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423 · cited 1×
“Investigators are using agents such as D-aminolevulinic acid to fluorescently label tumor cells to help assist surgeons during resection [113]; however, strategies such as this are also unlikely to allow surgeons to remove all tumor cells that have migrated away.”
BackgroundMaehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316 · cited 1×
“The most common types of chemotherapies under investigation include targeted molecular therapies, antiangiogenic therapies, immunotherapies, gene therapies, radiation-enhancement therapies, and drugs to overcome resistance (Table 3 and Figure 2) [101-104].”
BackgroundMulticolor Spectral Karyotyping of Human Chromosomes
Schröck, E., du Manoir, S., Veldman, T., Schoell, B., Wienberg, J., Ferguson-Smith, M. A., Ning, Y., Ledbetter, D. H., Bar-Am, I., Soenksen, D., et al. (1996) · Science · doi:10.1126/science.273.5274.494 · Cited by 1,755
Walker, M. D., Alexander, E., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., Norrell, H. A., Owens, G., Ransohoff, J., Wilson, C. B., et al. (1978) · Journal of Neurosurgery · doi:10.3171/jns.1978.49.3.0333 · Cited by 1,667
Walker, M. D., Green, S. B., Byar, D. P., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,611
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
Type 1 Neurofibromatosis Gene: Identification of a Large Transcript Disrupted in Three NF1 Patients
Wallace, M. R., Marchuk, D. A., Andersen, L. B., Letcher, R., Odeh, H. M., Saulino, A. M., Fountain, J. W., Brereton, A., Nicholson, J., Mitchell, A. L., et al. (1990) · Science · doi:10.1126/science.2134734 · Cited by 1,475
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Self-citationBrem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,330
Curran, W. J., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,310
(1991) · PubMed · Cited by 1,305
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Self-citationStummer, W., Reulen, H.-J., Meinel, T., Pichlmeier, U., Schumacher, W., Tonn, J.-C., Rohde, V., Oppel, F., Turowski, B., Woiciechowsky, C., et al. (2008) · Neurosurgery · doi:10.1227/01.neu.0000317304.31579.17 · Cited by 1,035
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · cited 1×
“This implies that combination therapies may be required to significantly target a specific pathway, or a combination of important pathways [106].”
BackgroundLong-term survival with glioblastoma multiforme
Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., et al. (2007) · Brain · doi:10.1093/brain/awm204 · Cited by 887
Fine, H. A., Dear, K. B. G., Loeffler, J. S., Mc Black, P. L., & Canellos, G. P. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s · Cited by 864
An analysis of dose-effect relationship in the radiotherapy of malignant gliomas
Walker, M. D., Strike, T. A., & Sheline, G. E. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90553-4 · Cited by 854
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849
Self-citationEpidemiology of primary brain tumors: Current concepts and review of the literature
Wrensch, M., Minn, Y., Chew, T., Bondy, M., & Berger, M. S. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.4.278 · Cited by 837
Radiotherapy for Glioblastoma in the Elderly
Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J.-S., Jadaud, E., Colin, P., Bondiau, P.-Y., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065901 · Cited by 792
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 740
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Rainov, N. G. (2000) · Human Gene Therapy · doi:10.1089/104303400750038499 · Cited by 698
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications
Burger, P. C., Vogel, F. S., Green, S. B., & Strike, T. A. (1985) · Cancer · doi:10.1002/1097-0142(19850901)56:5<1106::aid-cncr2820560525>3.0.co;2-2 · Cited by 651
Chang, C. H., Horton, J., Schoenfeld, D., Salazer, O., Perez-Tamayo, R., Kramer, S., Weinstein, A., Nelson, J. S., & Tsukada, Y. (1983) · Cancer · doi:10.1002/1097-0142(19830915)52:6<997::aid-cncr2820520612>3.0.co;2-2 · Cited by 598
Sugawa, N., Ekstrand, A. J., James, C. D., & Collins, V. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8602 · Cited by 594
PTEN: a tumour suppressor that functions as a phospholipid phosphatase
Maehama, T. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01519-6 · Cited by 590
Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A., & Van Meir, E. G. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00536.x · Cited by 569
Simpson, J. R., Horton, J., Scott, C., Curran, W. J., Rubin, P., Fischbach, J., Isaacson, S., Rotman, M., Asbell, S. O., Nelson, J. S., et al. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90203-8 · Cited by 535
Fisher, J. L., Schwartzbaum, J. A., Wrensch, M., & Wiemels, J. L. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.002 · Cited by 528
Mirimanoff, R.-O., Gorlia, T., Mason, W., Van den Bent, M. J., Kortmann, R.-D., Fisher, B., Reni, M., Brandes, A. A., Curschmann, J., Villa, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5963 · Cited by 509
Cancer Incidence in Five Continents. Comparability and quality of data.
Dm, P., & Cs, M. (1992) · PubMed · Cited by 505
Sotelo, J., Briceño, E., & López-González, M. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00008 · Cited by 505
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas
Brem, H., Mahaley, M. S., Vick, N. A., Black, K. L., Schold, S. C., Burger, P. C., Friedman, A. H., Ciric, I. S., Eller, T. W., Cozzens, J. W., et al. (1991) · Journal of Neurosurgery · doi:10.3171/jns.1991.74.3.0441 · Cited by 488
Shapiro, W. R., Green, S. B., Burger, P. C., Mahaley, M. S., Selker, R. G., VanGilder, J. C., Robertson, J. T., Ransohoff, J., Mealey, J., Strike, T. A., et al. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.71.1.0001 · Cited by 458
Valtonen, S., Timonen, U. L., Toivanen, P., Kalimo, H., Kivipelto, L., Heiskanen, O., Unsgaard, G., & Kuurne, T. (1997) · Neurosurgery · doi:10.1097/00006123-199707000-00011 · Cited by 426
Kristiansen, K., Hagen, S., Kollevold, T., Torvik, A., Holme, I., Stat, M., Nesbakken, R., Hatlevoll, R., Lindgren, M., Brun, A., et al. (1981) · Cancer · doi:10.1002/1097-0142(19810215)47:4<649::aid-cncr2820470405>3.0.co;2-w · Cited by 424
Westphal, M., Ram, Z., Riddle, V., Hilt, D., Bortey, E., & On behalf of the Executive Committee of the Gliadel® Study Group (2006) · Acta Neurochirurgica · doi:10.1007/s00701-005-0707-z · Cited by 420
on behalf of the Medical Research Council Brain Tumour Working Party, Bleehen, N., & Stenning, S. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.396 · Cited by 414
Sb, G., Byar, D. P., Walker, Pistenmaa, D. A., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., Mealey, J., Gl, O., et al. (1983) · PubMed · Cited by 404
Levin, V. A., Silver, P., Hannigan, J., Wara, W. M., Gutin, P. H., Davis, R. L., & Wilson, C. B. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90096-3 · Cited by 401
DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS
Brooks, W. H., Netsky, M. G., Normansell, D. E., & Horwitz, D. A. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.136.6.1631 · Cited by 368
Nagane, M., Levitzki, A., Gazit, A., Cavenee, W. K., & Huang, H.-J. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5724 · Cited by 363
Wu, J.-S., Zhou, L.-F., Tang, W.-J., Mao, Y., Hu, J., Song, Y.-Y., Hong, X.-N., & Du, G.-H. (2007) · Neurosurgery · doi:10.1227/01.neu.0000303189.80049.ab · Cited by 361
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 354
Proliferation of human malignant astrocytomas is dependent on Ras activation
Guha, A., Feldkamp, M. M., Lau, N., Boss, G., & Pawson, A. (1997) · Oncogene · doi:10.1038/sj.onc.1201455 · Cited by 337
Molecularly targeted therapy for malignant glioma
Sathornsumetee, S., Reardon, D. A., Desjardins, A., Quinn, J. A., Vredenburgh, J. J., & Rich, J. N. (2007) · Cancer · doi:10.1002/cncr.22741 · Cited by 325
By the Medical Research Council Brain Tumour Working Party (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.509 · Cited by 325
Godard, S., Getz, G. A., Delorenzi, M., Farmer, P. J., Kobayashi, H., Desbaillets, I., Nozaki, M., Diserens, A., Hamou, M., Dietrich, P., et al. (2003) · PubMed · Cited by 319
Miescher, S., Whiteside, T. L., Carrel, S., & von Fliedner, V (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.5.1899 · Cited by 312
Recent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 307
Self-citationRadiation and High-Dose Metronidazole in Supratentorial Glioblastomas
Urtasun, R., Band, P., Chapman, J. D., Feldstein, M. L., Mielke, B., & Fryer, C. (1976) · New England Journal of Medicine · doi:10.1056/nejm197606172942503 · Cited by 306
Wood, J. R., Green, S. B., & Shapiro, W. R. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.338 · Cited by 274
Adult glioma incidence trends in the United States, 1977–2000
Hess, K. R., Broglio, K. R., & Bondy, M. L. (2004) · Cancer · doi:10.1002/cncr.20621 · Cited by 270
Sathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E., McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3652 · Cited by 261
Selker, R. G., Shapiro, W. R., Burger, P., Blackwood, M. S., Deutsch, M., Arena, V. C., Van Gilder, J. C., Wu, J., Malkin, M. G., Mealey, J., et al. (2002) · Neurosurgery · doi:10.1097/00006123-200208000-00009 · Cited by 260
Nakamura, M. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1715 · Cited by 248
Belanich, M., Pastor, M., Randall, T., Guerra, D., Kibitel, J. T., Alas, L., Li, B., Citron, M. L., Wasserman, P., White, A., et al. (1996) · PubMed · Cited by 244
Shapiro, W. R., Green, S. B., Burger, P. C., Selker, R. G., VanGilder, J. C., Robertson, J. T., Mealey, J., Ransohoff, J., & Mahaley, M. S. (1992) · Journal of Neurosurgery · doi:10.3171/jns.1992.76.5.0772 · Cited by 243
Genetic pathways to glioblastomas
Ohgaki, H. (2005) · Neuropathology · doi:10.1111/j.1440-1789.2004.00600.x · Cited by 235 · cited 11×
“IV Age < 50, KPS < 90 Age > 50, resection, no neurologic deficits 11.1 V Age > 50, KPS 70 – 100, resection with neurologic deficits or only biopsy with > 54.4 Gy Age > 50, KPS < 70, no neurologic deficits 8.9 VI Age > 50, KPS 70 – 100, biopsy only with < 54.4 Gy Age > 50, KPS < 70, neurologic deficits 4.6”
BackgroundInfluentialComparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors
Louis, D. N., Deimling, A. V., Chung, R. Y., Rubio, M.-P., Whaley, J. M., Eibl, R. H., Ohgaki, H., Wiestler, O. D., Thor, A. D., & Seizinger, B. R. (1993) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199301000-00005 · Cited by 228
Faury, D., Nantel, A., Dunn, S. E., Guiot, M.-C., Haque, T., Hauser, P., Garami, M., Bognár, L., Hanzély, Z., Liberski, P. P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8626 · Cited by 225
Molecular pathogenesis of malignant gliomas
Ahmed Rasheed, B. K., Wiltshire, R. N., Bigner, S. H., & Bigner, D. D. (1999) · Current Opinion in Oncology · doi:10.1097/00001622-199905000-00004 · Cited by 219
Self-citationWrensch, M., Lee, M., Miike, R., Newman, B., Bargar, G., Davis, R., Wiencke, J., & Neuhaus, J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009154 · Cited by 218
Watts, G. S., Pieper, R. O., Costello, J. F., Peng, Y.-M., Dalton, W. S., & Futscher, B. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5612 · Cited by 214
Long-term use of cellular phones and brain tumours: increased risk associated with use for ⩾10 years
Hardell, L., Carlberg, M., Söderqvist, F., Mild, K. H., & Morgan, L. L. (2007) · Occupational and Environmental Medicine · doi:10.1136/oem.2006.029751 · Cited by 213
Hui, A. B.-Y., Lo, K.-W., Yin, X.-L., Poon, W.-S., & Ng, H.-K. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780280 · Cited by 211
He, J., Olson, J. J., & James, C. D. (1995) · PubMed · Cited by 188
Mahaley, M. S., Gentry, R. E., & Bigner, D. D. (1977) · Journal of Neurosurgery · doi:10.3171/jns.1977.47.1.0035 · Cited by 187
Self-citationChromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25.
Rasheed, B., McLendon, R. E., Friedman, H. S., Friedman, A. H., Fuchs, H. E., Bigner, D. D., & Bigner, S. H. (1995) · PubMed · Cited by 183
Self-citationDeutsch, M., Green, S. B., Strike, T. A., Burger, P. C., Robertson, J. T., Selker, R. G., Shapiro, W. R., Mealey, J., Ransohoff, J., Paoletti, P., et al. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90939-5 · Cited by 179
Nelson, D. F., Diener-West, M., Weinstein, A. S., Schoenfeld, D., Nelson, J. S., Sause, W. T., Chang, C. H., Goodman, R., & Carabell, S. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90321-4 · Cited by 173
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Desjardins, A., Reardon, D. A., Herndon, J. E., Marcello, J., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., Bailey, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0260 · Cited by 173
Self-citationWikstrand, C., Reist, C. J., Archer, G. E., Zalutsky, M. R., & Bigner, D. D. (1998) · Journal of Neurovirology · doi:10.3109/13550289809114515 · Cited by 172
Self-citationMechanisms of platelet-derived growth factor-induced chemotaxis
Rönnstrand, L., & Heldin, C. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(200002)9999:9999<::aid-ijc1136>3.0.co;2-j · Cited by 169
Brain tumours: classification and genes
Collins, V. P. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.040337 · Cited by 169
Willems, P. W. A., Taphoorn, M. J. B., Burger, H., van der Sprenkel, J. W. B., & Tulleken, C. A. F. (2006) · Journal of Neurosurgery · doi:10.3171/jns.2006.104.3.360 · Cited by 163
Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors
von Deimling, A., Fimmers, R., Schmidt, M. C., Bender, B., Faßbender, F., Nagel, J., Jahnke, R., Kaskel, P., Duerr, E., Koopmann, J., et al. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.544 · Cited by 151
Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., Merlo, A., & Van Meir, E. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203700 · Cited by 146
Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.
Chi, D. D., Merchant, R. E., Rand, R., Conrad, A. J., Garrison, D., Turner, R. R., Morton, D. L., & Hoon, D. S. �. (1997) · Europe PMC (PubMed Central) · Cited by 146
Different angiogenic phenotypes in primary and secondary glioblastomas
Karcher, S., Steiner, H. H., Ahmadi, R., Zoubaa, S., Vasvari, G. P., Bauer, H., Unterberg, A. W., & Herold‐Mende, C. C. (2005) · International Journal of Cancer · doi:10.1002/ijc.21648 · Cited by 145
Silber, J. R., Bobola, M. S., Ghatan, S., Blank, A., Kolstoe, D. D., & Berger, M. S. (1998) · PubMed · Cited by 144
Grossman, S. A., O’Neill, A., Grunnet, M. L., Mehta, M. P., Pearlman, J. L., Wagner, H., Gilbert, M. R., Newton, H. B., & Hellman, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.035 · Cited by 143
Zou, J.-P., Morford, L. A., Chougnet, C. A., Dix, A. R., Brööks, A. G., Torres, N., Shuman, J. D., Coligan, J. E., Brooks, W. H., Roszman, T. L., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4882 · Cited by 142
Glioma Immunology and Immunotherapy
Parney, I. F., Hao, C., & Petruk, K. C. (2000) · Neurosurgery · doi:10.1097/00006123-200004000-00002 · Cited by 142
The Neuro-Oncology Working Group of the German Cancer Society (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.509 · Cited by 142
EGFR gene amplification ‐ rearrangement in human glioblastomas
Schwechheimer, K., Huang, S., & Cavenee, W. K. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620206 · Cited by 135
Levin, V. A., Phuphanich, S., Yung, W. K. A., Forsyth, P. A., Maestro, R. F. D., Perry, J., Fuller, G. N., & Baillet, M. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9098-5 · Cited by 130
The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells.
Maier, D., Jones, G., Li, X., Schönthal, A. H., Gratzl, O., Meir, E. G. V., & Merlo, A. (1999) · PubMed · Cited by 129
Ruano, Y., Mollejo, M., Ribalta, T., Fiaño, C., Camacho, F. I., Gil‐Gómez, E., de Lope, Á. R., Hernández-Moneo, J.-L., Martínez, P., & Meléndez, B. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-39 · Cited by 123
Tumor antigens in astrocytic gliomas
Kurpad, S. N., Zhao., X. ‐., Wikstrand, C. J., Batra, S. K., McLendon, R. E., & Bigner, D. D. (1995) · Glia · doi:10.1002/glia.440150306 · Cited by 120
Self-citationNishizaki, T., Ozaki, S., Harada, K., Ito, H., Arai, H., Beppu, T., & Sasaki, K. (1998) · Genes Chromosomes and Cancer · Cited by 120
Immune responses in patients with gliomas.
Brooks, W. H., Caldwell, H. D., & Mortara, R. H. (1974) · PubMed · Cited by 118
Outcome and Cost of Craniotomy Performed to Treat Tumors in Regional Academic Referral Centers
Long, D. M., Gordon, T. A., Bowman, H. M., Etzel, A., Burleyson, G. P., Betchen, S. A., Garonzik, I. M., & Brem, H. (2003) · Neurosurgery · doi:10.1227/01.neu.0000057745.48813.93 · Cited by 112
Diagnosis and Treatment of High-Grade Astrocytoma
Sathornsumetee, S., Rich, J. N., & Reardon, D. A. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.004 · Cited by 109
(1974) · Journal of neurosurgery · doi:10.3171/jns.1974.41.3.0405 · Cited by 101
Brooks, W. H., Roszman, T. L., Mahaley, M. S., & Woosley, R. E. (1977) · PubMed Central · Cited by 97
Buckner, J. C., Ballman, K. V., Michalak, J. C., Burton, G. V., Cascino, T. L., Schomberg, P. J., Hawkins, R. B., Scheithauer, B. W., Sandler, H. M., Marks, R. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6979 · Cited by 92
Incidences of Gliomas and Meningiomas in Denmark, 1943 to 1997
Christensen, H. C., Kosteljanetz, M., & Johansen, C. (2003) · Neurosurgery · doi:10.1227/01.neu.0000064802.46759.53 · Cited by 89
Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma
Xie, D., Zeng, Y., Wang, H. J., Wen, J., Yu, T., Sham, J. S. T., & Guan, X. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602904 · Cited by 88
Capocaccia, R., Gatta, G., Roazzi, P., Carrani, E., Santaquilani, M., Angelis, R. D., & Tavilla, A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg751 · Cited by 86
Glioblastoma Multiforme and Anaplastic Astrocytoma
Pan, E., & Prados, M. D. (2003) · Cited by 78
Labuhn, M., Jones, G., Speel, E. M., Maier, D., Zweifel, C., Gratzl, O., Meir, E. G. V., Hegi, M. E., & Merlo, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204197 · Cited by 75
Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial
Urtasun, R. C., Feldstein, M., Partington, J., Tanasichuk, H., Miller, J. D., Russell, D. B., Agboola, O., & Mielke, B. W. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.171 · Cited by 69
Sampson, J. H., Akabani, G., Friedman, A. H., Bigner, D. D., Kunwar, S., Berger, M. S., & Bankiewicz, K. S. (2006) · Neurosurgical FOCUS · doi:10.3171/foc.2006.20.4.9 · Cited by 64
Self-citationMalignant glioma: Neuropathology and Neurobiology
Preusser, M., Haberler, C., & Hainfellner, J. A. (2006) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-006-0304-7 · Cited by 63
Elliott, L. H., Brooks, W. H., & Roszman, T. L. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114719 · Cited by 60
Roszman, T. L., Brooks, W. H., & Elliott, L. H. (1982) · Cancer · Cited by 55
Inhibiting kinases in malignant gliomas
Chi, A. S., & Wen, P. Y. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.473 · Cited by 54
The glioblastoma multiforme in Georgia, 1977–1981
McLendon, R. E., Robinson, J. S., Chambers, D. B., Grufferman, S., & Burger, P. C. (1985) · Cancer · Cited by 46
Radiochemotherapy in Patients With Primary Glioblastoma Comparing Two Temozolomide Dose Regimens
Combs, S. E., Wagner, J., Bischof, M., Welzel, T., Edler, L., Rausch, R., Wagner, F., Bois, A. Z.-D., Debus, J., & Schulz-Ertner, D. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.064 · Cited by 42
Fine structural characterization of melanosomes in dysplastic nevi
Takahashi, H., Horikoshi, T., & Jimbow, K. (1985) · Cancer · doi:10.1002/1097-0142(19850701)56:1<41::aid-cncr2820560108>3.0.co;2-w · Cited by 37
Vecht, C. J., van den Bent, M. J., & Lacombe, D. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00451-8 · Cited by 23
Cited by
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Sımjee, S. U. (2017) · PubMed · doi:10.22034/apjcp.2017.18.1.3 · Cited by 1,231
Mao, P., Joshi, K., Li, J., Kim, S.-H., Li, P., Santana-Santos, L., Luthra, S., Chandran, U. R., Benos, P. V., Smith, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221478110 · Cited by 642
Current concepts and management of glioblastoma
Preusser, M., de Ribaupierre, S., Wöhrer, A., Erridge, S. C., Hegi, M., Weller, M., & Stupp, R. (2011) · Annals of Neurology · doi:10.1002/ana.22425 · Cited by 461
Glutamate and the biology of gliomas
de Groot, J., & Sontheimer, H. (2011) · Glia · doi:10.1002/glia.21113 · Cited by 293
Metadata
- Authors
- Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2009-06-26
- Volume
- 18
- Issue
- 8
- Pages
- 1061-1083
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2086120407
- Cited by
- 550
- References
- 130
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.